Research has shed light on how a new type of antibody treatment reactivates patients' immune cells to fight ovarian cancer.

Moreover, the panelists emphasized that real-world evidence goes beyond clinical trial data. It involves continuous patient monitoring, proactive adverse effect management, and adapting protocols ...

OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three months ended March 31, 2025 after the close of the U.S. financial markets on Thursday, May 8, 2025, and will hold a conference ...

A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team ...

With an arsenal of antibody assets based on IgE, IgA, and IgG, the newly combined company has opportunities across cancer indications.

BriaPro has filed US patent applications for this technology ...

Full abstract details including title and text are currently available to registrants via the AACR online itinerary planner. A copy of the presentation will be available in the Posters and ...

At ESCMID Global 2025 in Vienna, AstraZeneca will present a comprehensive data package from its Vaccines & Immune Therapies portfolio, featur ...

Researchers have engineered Lyme bacterial protein, CspZ, to produce a robust immune response in mice for vaccine development.

Global Bispecific Trispecific Antibodies Market Size Will Surpass US$ 50 Billion By 2030 Says Kuick ResearchDelhi, April 04, 2025 (GLOBE NE ...

If preclinical findings were translated into the clinic, they could shorten the CAR-T generation lead time from two weeks to ...

Explore how machine learning is transforming immunology—from epitope prediction to smarter vaccine design—plus key challenges ...